Published in Eur J Cancer on September 01, 1995
Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol (2006) 2.19
Current management of gallbladder carcinoma. Oncologist (2010) 1.83
Hepatocellular carcinoma. Postgrad Med J (2000) 1.67
Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer (2005) 1.47
Management of hilar cholangiocarcinoma in the North of England: pathology, treatment, and outcome. World J Gastroenterol (2005) 1.17
Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. Invest New Drugs (2004) 1.14
Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma. BMC Cancer (2006) 1.11
Outpatient therapy with gemcitabine and docetaxel for gallbladder, biliary, and cholangio-carcinomas. Invest New Drugs (2002) 1.03
Gallbladder Cancer in the 21st Century. J Oncol (2015) 1.02
Epirubicin, cisplatin, and protracted infusion of 5-FU (ECF) in advanced intrahepatic cholangiocarcinoma. J Cancer Res Clin Oncol (2004) 0.98
Photodynamic therapy is associated with an improvement in survival in patients with irresectable hilar cholangiocarcinoma. HPB (Oxford) (2009) 0.98
Prognostic analysis of surgical treatment of peripheral cholangiocarcinoma: two decades of experience at Chang Gung Memorial Hospital. World J Gastroenterol (2005) 0.98
Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness. Invest New Drugs (2010) 0.96
Guidelines for chemotherapy of biliary tract and ampullary carcinomas. J Hepatobiliary Pancreat Surg (2008) 0.94
Surgery and chemotherapy for intrahepatic cholangiocarcinoma. World J Hepatol (2010) 0.94
Surgical strategy for bile duct cancer: Advances and current limitations. World J Clin Oncol (2011) 0.92
Rational therapeutic strategy for T2 gallbladder carcinoma based on tumor spread. World J Gastroenterol (2010) 0.88
EGFR expression in gallbladder carcinoma in North America. Int J Med Sci (2008) 0.88
A phase II FOLFOX-4 regimen as second-line treatment in advanced biliary tract cancer refractory to gemcitabine/cisplatin. J Chemother (2013) 0.88
Low-dose paclitaxel inhibits the induction of epidermal-mesenchymal transition in the human cholangiocarcinoma CCKS-1 cell line. Oncol Lett (2013) 0.85
Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma. World J Gastroenterol (2014) 0.84
Advances in the management of biliary tract cancers. Clin Adv Hematol Oncol (2013) 0.84
Tumors of ampulla of Vater: A case series and review of chemotherapy options. World J Gastrointest Oncol (2012) 0.84
Doxorubicin and 5-fluorouracil resistant hepatic cancer cells demonstrate stem-like properties. Cytotechnology (2012) 0.81
Successful treatment of unresectable gallbladder cancer with low-dose paclitaxel as palliative chemotherapy after failure of gemcitabine and oral S-1: A case report. Oncol Lett (2012) 0.81
Interleukin-2 gene-encoded stromal cells inhibit the growth of metastatic cholangiocarcinomas. World J Gastroenterol (2006) 0.79
Long-term complete response of multiple hepatic metastases from carcinoma of the papilla of Vater using intrahepatic infusion of 5-FU with low-dose cisplatin following pancreaticoduodenectomy. Int J Clin Oncol (2008) 0.77
Clinical results of intra-arterial adjuvant chemotherapy for prevention of liver metastasis following curative resection of biliary tract cancer. HPB (Oxford) (2008) 0.75
Comparison of the Efficacy between Gemcitabine-Cisplatin and Capecitabine-Cisplatin Combination Chemotherapy for Advanced Biliary Tract Cancer. Cancer Res Treat (2014) 0.75
Targeted therapy in biliary tract cancers-current limitations and potentials in the future. J Gastrointest Oncol (2017) 0.75
Phase I study of weekly palliative chemotherapy with low-dose third-line paclitaxel for biliary tract cancer. Mol Clin Oncol (2017) 0.75
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet (2000) 12.56
Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med (1996) 7.06
On the Interpretation of Multi-Hit Survival Curves. Proc Natl Acad Sci U S A (1949) 5.96
Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol (1997) 5.89
Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer (2001) 5.36
Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med (1998) 5.08
Insulin biosynthesis: evidence for a precursor. Science (1967) 5.05
Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet (2001) 5.01
Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst (1998) 4.65
Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol (2002) 3.98
Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol (2002) 3.91
Biotechnology awareness study, Part 1: Where scientists get their information. Bull Med Libr Assoc (1991) 3.85
Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res (2000) 3.41
Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer (1998) 3.36
Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol (2009) 3.33
Effect of reactive pharmacy intervention on quality of hospital prescribing. BMJ (1990) 3.25
Heterogeneity of microsatellite mutations within and between loci, and implications for human demographic histories. Genetics (1998) 3.12
Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol (2003) 3.10
Genetic manipulation of centromere function. Mol Cell Biol (1987) 2.97
Equatorius: a new hominoid genus from the Middle Miocene of Kenya. Science (1999) 2.92
C-type virus released from cultured human rhabdomyosarcoma cells. Nat New Biol (1972) 2.78
Guidelines for perioperative care in elective colonic surgery: Enhanced Recovery After Surgery (ERAS(®)) Society recommendations. World J Surg (2013) 2.77
Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol (1996) 2.76
A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol (1997) 2.71
Infectious complications of subcutaneous interleukin-2 and interferon-alpha. Lancet (1992) 2.65
A simple method for the determination of oestrogen receptor concentrations in breast tumours and other tissues. Clin Chim Acta (1975) 2.64
Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension (2000) 2.55
Failure of early diagnosis in symptomatic Duchenne muscular dystrophy. Lancet (1999) 2.49
Identification of the class I genes of the mouse major histocompatibility complex by DNA-mediated gene transfer. Nature (1982) 2.48
Radiographic interpretation by nurse practitioners in a minor injuries unit. J Accid Emerg Med (1996) 2.44
Is a low leptin concentration, a low resting metabolic rate, or both the expression of the "thrifty genotype"? Results from Mexican Pima Indians. Am J Clin Nutr (1998) 2.42
A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol (2005) 2.41
Effects of gender, body composition, and menopause on plasma concentrations of leptin. J Clin Endocrinol Metab (1996) 2.40
Validation of the Arizona Activity Frequency Questionnaire using doubly labeled water. Med Sci Sports Exerc (2001) 2.40
The use of out of hours health services: a cross sectional survey. BMJ (1998) 2.36
Bile acid transformations by microbial strains belonging to genera found in intestinal contents. Acta Pathol Microbiol Scand (1967) 2.33
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 2.31
Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol (2000) 2.29
Perinatal hypoxic-ischemic thalamic injury: clinical features and neuroimaging. Ann Neurol (1998) 2.29
Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet (1991) 2.26
Guidelines for perioperative care in elective colonic surgery: Enhanced Recovery After Surgery (ERAS®) Society recommendations. Clin Nutr (2012) 2.25
From quantity to quality: the central cardiac audit database project. Heart (1999) 2.23
Chromatin conformation of yeast centromeres. J Cell Biol (1984) 2.19
A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol (1998) 2.18
Prediction of progression to AIDS with serum HIV-1 RNA and CD4 count. Lancet (1995) 2.17
Global impact of influenza virus on cellular pathways is mediated by both replication-dependent and -independent events. J Virol (2001) 2.13
Management of carcinomas of the upper gastrointestinal tract. BMJ (1994) 2.12
Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol (2000) 2.12
Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens. Eur J Cancer (1996) 2.11
Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist. Lancet (1987) 2.09
Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol (1996) 2.08
Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer. J Clin Oncol (1995) 2.08
A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol (1994) 2.02
Detection of ambulatory ischaemia is not of practical clinical value in the routine management of patients with stable angina. A long-term follow-up study. Eur Heart J (1995) 1.97
Measles, mumps, and rubella vaccination. BMJ (1992) 1.96
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer (2004) 1.94
Replication-defective chimeric helper proviruses and factors affecting generation of competent virus: expression of Moloney murine leukemia virus structural genes via the metallothionein promoter. Mol Cell Biol (1987) 1.94
Ataxia-telangiectasia: an interdisciplinary approach to pathogenesis. Medicine (Baltimore) (1991) 1.89
Magnetic resonance imaging volumes of the hippocampus and the amygdala in women with borderline personality disorder and early traumatization. Arch Gen Psychiatry (2000) 1.88
Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol (1995) 1.87
Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. Aliment Pharmacol Ther (1997) 1.86
Reproducibility of measurements of oestrogen-receptor concentration in breast cancer. Br J Cancer (1977) 1.85
Glucose-6-phosphate dehydrogenase deficiency and malaria. J Mol Med (Berl) (1998) 1.83
The milk-ejection reflex of the rat: an intermittent function not abolished by surgical levels of anaesthesia. J Endocrinol (1973) 1.82
CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer (2005) 1.81
Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer (1999) 1.80
Proliferation of human lymphocytes in culture. Nature (1966) 1.76
A comparison of treatment planning techniques used in two randomised UK external beam radiotherapy trials for localised prostate cancer. Clin Oncol (R Coll Radiol) (2007) 1.75
Identification of a BALB/c H-2Ld gene by DNA-mediated gene transfer. Science (1982) 1.72
The course of anxiety, depression and drinking behaviours after completed detoxification in alcoholics with and without comorbid anxiety and depressive disorders. Alcohol Alcohol (2001) 1.69
HIV positive patients first presenting with an AIDS defining illness: characteristics and survival. BMJ (1995) 1.69
Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.68
A test for the practical evaluation of male fertility by acridine orange (AO) fluorescence. Fertil Steril (1984) 1.68
FDG-PET in the prediction of survival of patients with cancer of the pancreas: a pilot study. Br J Cancer (2000) 1.68
Changes in serum osteocalcin, plasma phylloquinone, and urinary gamma-carboxyglutamic acid in response to altered intakes of dietary phylloquinone in human subjects. Am J Clin Nutr (1997) 1.68